XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.21.1

COMMITMENTS AND CONTINGENCIES (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract] |
Schedule of Contingent Consideration | A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2021 and March 31, 2020 is as follows (in thousands):
Three Months Ended March 31, 2021 | Contingent Consideration Liability Related to Acquisition of: |  |  |
Arkis |  | Derma Sciences |  |  | ACell Inc. (See Note 2) | Location in Financial Statements |  |
| Short-term |  | Long-term |  | Long-term |  |  | Long-term |  |  |
Balance as of January 1, 2021 | $ | 3,415 |  |  | $ | 11,746 |  |  | $ | 230 |  |  |  | $ | — |  |  |  |
Additions from acquisition of ACell | — |  |  | — |  |  | — |  |  |  | 23,900 |  |  |  |
Loss from change in fair value of contingent consideration liabilities | 17 |  |  | $ | 265 |  |  | — |  |  |  | — |  | Research and development |  |
Balance as of March 31, 2021 | $ | 3,432 |  |  | $ | 12,011 |  |  | $ | 230 |  |  |  | $ | 23,900 |  |  |  |
Three Months Ended March 31, 2020 | Contingent Consideration Liability Related to Acquisition of: |
Arkis |  | Derma Sciences | Location in Financial Statements
| Long-term |  | Long-term |
Balance as of January 1, 2020 | $ | 14,210 |  |  | $ | 230 |  |
Loss from change in fair value of contingent consideration liabilities | (1,051) |  |  | — |  | Research and development
Balance as of March 31, 2020 | $ | 13,159 |  |  | $ | 230 |  |

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration